Canaccord Genuity Reaffirms Their Buy Rating on Adicet Bio (ACET)
Canaccord Genuity has reaffirmed a Buy rating on Adicet Bio (ACET) with a price target of $8.00. Analyst John Newman, who covers the Healthcare sector, has an average return of -1.6% and a 36.60% success rate on his recommendations. The overall analyst consensus for Adicet Bio is a Strong Buy, with an average price target of $6.50.
In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Adicet Bio, with a price target of $8.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Newman covers the Healthcare sector, focusing on stocks such as Delcath Systems, Arcellx Inc, and Regeneron. According to TipRanks, Newman has an average return of -1.6% and a 36.60% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Adicet Bio with a $6.50 average price target.
